Min Wang

40.8k total citations · 6 hit papers
702 papers, 16.6k citations indexed

About

Min Wang is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Min Wang has authored 702 papers receiving a total of 16.6k indexed citations (citations by other indexed papers that have themselves been cited), including 345 papers in Molecular Biology, 185 papers in Cancer Research and 123 papers in Oncology. Recurrent topics in Min Wang's work include Cancer-related molecular mechanisms research (95 papers), MicroRNA in disease regulation (83 papers) and Circular RNAs in diseases (53 papers). Min Wang is often cited by papers focused on Cancer-related molecular mechanisms research (95 papers), MicroRNA in disease regulation (83 papers) and Circular RNAs in diseases (53 papers). Min Wang collaborates with scholars based in China, United States and United Kingdom. Min Wang's co-authors include Xi Jiang, Mary K. Estes, Haifeng Zhang, George Hajishengallis, Martha Triantafilou, Richard G. Pestell, Mark E. Stearns, Kathy Triantafilou, Shuang Liang and Anton M. Bennett and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Min Wang

673 papers receiving 16.4k citations

Hit Papers

The Imprinted H19 LncRNA ... 1993 2026 2004 2015 2013 1993 2019 2018 2022 250 500 750

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Min Wang 9.0k 5.5k 2.7k 2.4k 1.5k 702 16.6k
Xin Zhang 10.3k 1.1× 5.6k 1.0× 3.5k 1.3× 2.1k 0.9× 2.3k 1.5× 980 19.1k
Qing Li 6.0k 0.7× 4.2k 0.8× 2.8k 1.0× 2.4k 1.0× 1.9k 1.2× 533 13.2k
Behzad Baradaran 11.7k 1.3× 5.3k 1.0× 4.1k 1.5× 3.3k 1.4× 1.4k 0.9× 648 21.2k
Hamed Mirzaei 10.3k 1.1× 6.4k 1.2× 1.7k 0.6× 1.9k 0.8× 918 0.6× 359 17.9k
Xin Wang 13.1k 1.5× 5.2k 1.0× 4.2k 1.5× 4.0k 1.7× 2.3k 1.5× 1.1k 24.4k
Adriana Albini 10.2k 1.1× 4.6k 0.8× 7.0k 2.6× 4.0k 1.7× 1.4k 0.9× 396 22.9k
Justin R. Cross 12.9k 1.4× 4.8k 0.9× 2.1k 0.8× 3.4k 1.4× 1.1k 0.7× 92 19.6k
Qi Zhang 7.7k 0.8× 4.4k 0.8× 3.8k 1.4× 3.3k 1.4× 1.3k 0.9× 663 16.7k
Hui Wang 6.7k 0.7× 2.0k 0.4× 2.7k 1.0× 3.7k 1.5× 931 0.6× 708 16.0k
Yong Song Gho 13.4k 1.5× 5.5k 1.0× 974 0.4× 2.6k 1.1× 1.1k 0.7× 156 18.3k

Countries citing papers authored by Min Wang

Since Specialization
Citations

This map shows the geographic impact of Min Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Min Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Min Wang more than expected).

Fields of papers citing papers by Min Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Min Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Min Wang. The network helps show where Min Wang may publish in the future.

Co-authorship network of co-authors of Min Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Min Wang. A scholar is included among the top collaborators of Min Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Min Wang. Min Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Jing, et al.. (2025). Immunotherapy benefits PD‑L1‑positive gastric‑type endocervical adenocarcinoma: A multicenter, retrospective study. Molecular and Clinical Oncology. 22(6). 1–8. 1 indexed citations
2.
Huang, Wenjuan, Jingzi ZhangBao, Lei Zhou, et al.. (2025). Eculizumab for the acute attack of neuromyelitis optica spectrum disorder. Frontiers in Immunology. 16. 1645401–1645401.
4.
Cao, Ying, Zhen Tian, Tiantian Zhang, et al.. (2024). Aqueous humor cytokine levels in patients with subretinal fibrosis in neovascular age-related macular degeneration. BMC Ophthalmology. 24(1). 335–335.
5.
Wang, Min, Xi Rao, Simone Gaedicke, et al.. (2024). Adding a PPARα Agonist Enhances T Cell-Mediated Effects of RT in Combination with Anti-PD-1. International Journal of Radiation Oncology*Biology*Physics. 120(2). e409–e410. 1 indexed citations
7.
Song, Shuting, Zhicheng Zhu, Yan Zhu, et al.. (2024). Comparison of singleton and twin birth weight reference percentile curves by gestational age and sex in extremely preterm infants: a population-based study. BMJ Paediatrics Open. 8(1). e002502–e002502. 1 indexed citations
8.
Yin, Sheng, Bingqi Wang, Zeyou Wang, et al.. (2024). Reliability of Droplet Digital PCR Alone and in Combination with Interleukin-6 and Procalcitonin for Prognosis of Bloodstream Infection. Infection and Drug Resistance. Volume 17. 1051–1071. 5 indexed citations
9.
Liu, Ze, et al.. (2023). Global trends and current status in pheochromocytoma: a bibliometric analysis of publications in the last 20 years. Frontiers in Endocrinology. 14. 1167796–1167796. 2 indexed citations
10.
Li, Xiaotao, et al.. (2023). Policy analysis in the field of rare diseases in China: a combined study of content analysis and Bibliometrics analysis. Frontiers in Medicine. 10. 1180550–1180550. 6 indexed citations
11.
Wang, Min, et al.. (2023). Research progress of circRNA in malignant tumour metabolic reprogramming. RNA Biology. 20(1). 641–651. 12 indexed citations
12.
Hao, Wei, et al.. (2023). Astragalus polysaccharide ameliorates insulin resistance in HepG2 cells through activating the STAT5/IGF‐1 pathway. Immunity Inflammation and Disease. 11(11). e1071–e1071. 11 indexed citations
13.
Wang, Xiaosong, Lei Xing, Rui Yang, et al.. (2021). The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC. Molecular Cancer. 20(1). 91–91. 77 indexed citations
14.
Wang, Yun, Min Wang, Hao‐Xiang Wu, & Rui‐Hua Xu. (2021). Advancing to the era of cancer immunotherapy. Cancer Communications. 41(9). 803–829. 137 indexed citations
15.
Cheng, Jin, Sijia He, Min Wang, et al.. (2019). The Caspase-3/PKCδ/Akt/VEGF-A Signaling Pathway Mediates Tumor Repopulation during Radiotherapy. Clinical Cancer Research. 25(12). 3732–3743. 38 indexed citations
16.
Mao, Chao, Xiang Wang, Yating Liu, et al.. (2018). A G3BP1-Interacting lncRNA Promotes Ferroptosis and Apoptosis in Cancer via Nuclear Sequestration of p53. Cancer Research. 78(13). 3484–3496. 402 indexed citations breakdown →
17.
Xu, Feng, Jing Liu, Di Liu, et al.. (2014). LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses. Cancer Research. 74(13). 3418–3428. 293 indexed citations
18.
Guo, Xingjun, Min Wang, Jianxin Jiang, et al.. (2013). Balanced Tiam1-Rac1 and RhoA Drives Proliferation and Invasion of Pancreatic Cancer Cells. Molecular Cancer Research. 11(3). 230–239. 31 indexed citations
19.
Li, Zhiping, Xuanmao Jiao, Chenguang Wang, et al.. (2010). Alternative Cyclin D1 Splice Forms Differentially Regulate the DNA Damage Response. Cancer Research. 70(21). 8802–8811. 94 indexed citations
20.
Tian, Lifeng, Jie Zhou, Mathew C. Casimiro, et al.. (2009). Activating Peroxisome Proliferator-Activated Receptor γ Mutant Promotes Tumor Growth In vivo by Enhancing Angiogenesis. Cancer Research. 69(24). 9236–9244. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026